Mark Wong, MD
Internal Medicine · Phoenix, AZNPI 1821054081
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Gilead accounts for 81.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $14,036 and has fallen 56.8% since, to $6,066 in 2025. Among internal medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $238.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$58K
- Mallinckrodt Hospital Products Inc.$4K
- Sirtex Medical Inc$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Madrigal Pharmaceuticals$1K
- AbbVie$457
- plus $2K from 23 others
Across 9 payments — averaging $6085.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$24K
- Mallinckrodt Enterprises LLC$18K
- Mallinckrodt Hospital Products Inc.$13K
What the payments were for
- Consulting fees$14,78021%
- Speaking & faculty fees$38,55054%
- Travel & lodging$4,2356%
- Food & beverage$13,25019%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 187 | $57,572 |
| Mallinckrodt Hospital Products Inc. | 9 | $3,915 |
| Sirtex Medical Inc | 3 | $3,770 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $2,142 |
| Madrigal Pharmaceuticals | 10 | $1,229 |
| AbbVie | 6 | $457 |
| Ipsen Biopharmaceuticals, Inc | 2 | $275 |
| Intercept Pharmaceuticals, Inc. | 4 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $142 |
| Intra-sana Laboratories | 4 | $141 |
| Shionogi Inc | 2 | $127 |
| Bayer | 2 | $118 |
| Dova Pharmaceuticals | 1 | $113 |
| Sanofi | 1 | $111 |
| Mallinckrodt Enterprises LLC | 2 | $109 |
| E.r. Squibb & Sons, L.L.C. | 2 | $79 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Johnson & Johnson | 2 | $49 |
| Fujifilm Healthcare Americas Corporation | 2 | $46 |
| Trisalus Life Sciences, Inc. | 1 | $41 |
| Bristol Myers Squibb | 2 | $29 |
| AstraZeneca | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $22 |
| Vibrant Gastro, Inc. | 1 | $20 |
| Exact Sciences | 1 | $17 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vemlidy$31,009
- Livdelzi$4,163
- SIR-Spheres Microspheres$3,680
- XIFAXAN$1,234
- REZDIFFRA$968
- TERLIVAZ$720
- Epclusa$497
- Mavyret$342
- IQIRVO$275
- LIVTENCITY$124
- RESMETIROM$115
- DOPTELET$113
- THYMOGLOBULIN$111
- Mulpleta$110
- Nexavar$105
- Harvoni$103
How this compares
$70,833 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 22 | $253,899 |
| VemlidyTenofovir Alafenamide | 120 | $190,677 |
| XifaxanRifaximin | 41 | $171,818 |
| Ursodiol | 240 | $82,991 |
| EliquisApixaban | 22 | $28,596 |
| Mycophenolate Mofetil | 289 | $26,753 |
| CreonLipase/Protease/Amylase | 14 | $26,540 |
| Tacrolimus | 311 | $22,113 |
| Adefovir Dipivoxil | 16 | $19,301 |
| Sirolimus | 50 | $11,467 |
| Entecavir | 74 | $9,666 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $8,636 |
| Tenofovir Disoproxil Fumarate | 34 | $8,196 |
| Everolimus | 13 | $4,589 |
| Valganciclovir Hcl | 25 | $4,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $171 | $253,89922 claims |
| GileadVemlidy | $57,572 | $190,677120 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $2,142 | $171,81841 claims |
| AbbVieCreon | $457 | $26,54014 claims |
| AstraZenecaLokelma | $25 | $8,63614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Phoenix
- Frank LovecchioPhoenix$911K
- Nasser HajaigPhoenix$687K
- Kelly KrohnPhoenix$262K
- Paul StanderPhoenix$222K
- Howard GrossmanPhoenix$131K
- Nafis Shamsid-DeenPhoenix$115K
- Shishir MurarkaPhoenix$79K
- Geoffrey OrmePhoenix$27K
- Roberto RuizPhoenix$25K
- Louise TaberPhoenix$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.